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Reply to ‘‘Biliary atresia: Does ethnicity matter?’’
To the Editor:
We welcome the comment of Girard et al. [1] to our systematic
review on the epidemiology of primary sclerosing cholangitis
(PSC) and primary biliary cirrhosis (PBC) [2]. The authors under-
score the need for proper assessment of ethnicity in epidemiolog-
ical studies of rare diseases such as biliary atresia, PSC, and PBC.
The apparent familial risk, albeit with a low absolute risk,
together with the reported genetic risk loci, point in the direction
of a complex genetic predisposition belying both PSC and PBC.
Recently, disparate associations with several genetic risk loci
have been reported in PSC patients from various ethnic back-
grounds [3]. For PBC, little is known about ethnic differences
since the majority of studies have been performed with Cauca-
sian patients. Notably, a large multicenter study in the US was
performed comparing PBC patients with geographically and eth-
nically diverse backgrounds [4]. The authors showed more severe
disease in African Americans and Hispanics compared to Cauca-
sians. In addition, for inﬂammatory bowel disease, which is clo-
sely associated with PSC, it has been well documented that
incidence rates in 2nd generation immigrants with a different
ethnic background assume the same levels as those for the indig-
enous population, pointing towards environmental factors [5–7].
For PSC, population-based trends in incidence and prevalence
rates with regard to ethnic background are lacking. One study
from Southern Israel reported higher prevalence rates for PBC
among Jews and immigrants compared to Arabs and native Israe-
lis and in a study from Southeast Asia, the prevalence rate in the
Chinese population was almost twice as high as in the Malay pop-
ulation, though the small number of included patients is a limita-
tion of both studies. [8,9] The data presented by Girard et al. [1]
exemplify our conclusion that large true population-based epide-
miological studies with meticulous case-ﬁnding, case-ascertain-
ment, as well as detailed phenotyping (including ancestry) are
needed to provide clues for unraveling genetic and environmen-
tal risk factors for these diseases.
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Statin hepatotoxicity and the dilemma of causality in rare
hepatic adverse drug reactions
To the Editor:
In his editorial, Bader [1] highlights the problems associated with
assessing statin-induced hepatotoxicity, a rare hepatic adverse
drug reaction (ADR). However, the deﬁnitions of hepatotoxicity
and idiosyncratic reactions are used by Bader in a confusing
way. With the appraisal ‘‘Yes! Statins can be given to liver
patients’’ Bader also creates the impression that statins are
withheld from patients with liver disease [1]. At least outside
the US, however, mainstream physicians including hepatologists
never had a problem prescribing statins to their liver patients;
uncertainty exists only how to proceed in cases of decompen-
sated liver cirrhosis.
Björnsson et al. [2] have clearly shown that statins can cause
idiosyncratic hepatotoxicity. In general, drug hepatotoxicity
refers to either of two different underlying reactions, namely
the dose dependent, predictable, and hence intrinsic reaction,
or the dose independent, unpredictable, and hence idiosyncratic
one. Limiting ‘‘hepatotoxicity’’ to the dose dependent reaction
leaves the reader with the impression that statins are not hepa-
totoxic due to lack of dose dependency [1]; on the contrary, statin
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metabolism is reduced in patients with preexisting liver disease
and statins are known to increase ALT [3,4], with a slight dose
dependency of ALT increase for higher statin doses ([4], Table 3).
At no time did Björnsson et al. [2] claim a dose dependent sta-
tin hepatotoxicity, but described a rare, severe idiosyncratic
statin hepatotoxicity; reexposure with similar symptoms nearly
proves a causal relationship. Bader should have withdrawn his
previous statement concerning the myth of statin hepatotoxicity
[5], because this proposal was incorrect and misleading; consid-
ering the very low incidence in clinical studies, spontaneous
reports, and case reports, the decision still will result in prescrib-
ing statins rather than withholding them.
Most systems to detect rare ADRs rely upon active reporting
systems where cases are only included if physicians suspect a
causal relationship. These systems are heavily biased toward
assuming causality even if this does not exist; the dilemma of
prejudice and selective data reporting, as is prevalent for other
cases of potential hepatotoxicity by drugs and herbs, was ele-
gantly solved by Björnsson et al. using the diagnostic algorithm
of CIOMS, also called RUCAM [2]. Despite its known shortcom-
ings, this causality assessment method has been used extensively
to evaluate hepatotoxicity by drugs [6]. In relation to the study on
statin hepatotoxicity by Björnsson et al. [2], the applied method
of CIOMS/RUCAM was considered the best method available for
this inquiry [1].
Björnsson et al. [2] identiﬁed cases of idiosyncratic hepatotox-
icity due to statins and discussed their results regarding previous
reports on other cases of statin hepatotoxicity. This conﬁrms that
package inserts of warnings about the rare hepatotoxicity
problem should remain, as opposed to the viewpoint of Bader
who prefers its deletion [5]. The cautionary statement is valuable
information for physicians and patients and a preventive
measure for legal consequences that otherwise may reach statin
manufacturers in cases of statin hepatotoxicity.
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Reply to: ‘‘Statin hepatotoxicity and the dilemma of causality
in rare hepatic adverse drug reactions’’
To the Editor:
ALT monitoring for statins no longer recommended
It is gratifying that since the publication of my editorial review on
statins and the liver (February 2012 issue of the Journal), the USA
Food and Drug Administration (FDA) announced on 28 February
2012, a marked relaxation of package insert language on all stat-
ins [1]. Since pharmaceutical safety boards of many countries clo-
sely follow the insert language of the FDA, these revisions will be
of interest to a worldwide audience.
What was previously a hodge-podge of comments about the
liver that differed for each statin, the discussion has been greatly
redacted and made uniform. Brieﬂy, the statin labels no longer
recommend ALT monitoring after starting a statin. Should acute
liver disease develop, the statin should be withheld until the
cause is ascertained. This would imply that the patient should
be told before treatment about possible signs of drug-induced
liver injury and urged to inform the physician if these symptoms
occur. The label reminds the reader that an ALT elevation can also
occur from muscle injury.
These changes represent a seismic shift in policy. The FDA
clearly agrees that an elevated ALT after initiating a statin is
not a sign of hepatotoxicity. Instead, the shift in monitoring for
symptoms follows the same successful approach as for isoniazid
monitoring. I have advocated these changes for some time [2–4].
Still, the labels advise that liver tests be checked prior to ini-
tiating a statin, and that statins should not be given to patients
with ‘‘active liver disease.’’ The phrase ‘‘active liver disease’’ is
not deﬁned on the label nor anywhere else I am aware of.
The correspondents and I both agree that statins can be given
to patients with chronic liver disease. There is reasonable dis-
agreement over use in decompensated liver patients simply due
to a lack of data. However, data are starting to appear. In Spain,
Abraldes et al. gave 40 mg of simvastatin or placebo to 60 cirrho-
tics with portal hypertension (proved by WHVP) in a randomized
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